Edouard Louis, Shaji Sebastian, Britta Siegmund, Peter Bossuyt, Silvio Danese, Nanne de Boer, Edward V Loftus, Bjørn Moum, Laurent Peyrin-Biroulet, Stefan Schreiber, Jie Zhou, Edith Angellotti, Shashi Adsul, Stephen Jones, Corey A Siegel
{"title":"Long-term safety of vedolizumab in patients with ulcerative colitis/Crohn's disease: A prospective observational study.","authors":"Edouard Louis, Shaji Sebastian, Britta Siegmund, Peter Bossuyt, Silvio Danese, Nanne de Boer, Edward V Loftus, Bjørn Moum, Laurent Peyrin-Biroulet, Stefan Schreiber, Jie Zhou, Edith Angellotti, Shashi Adsul, Stephen Jones, Corey A Siegel","doi":"10.1016/j.cgh.2025.10.006","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>This post-authorization safety study compared long-term safety of vedolizumab or other biologics in patients with ulcerative colitis (UC) or Crohn's disease (CD).</p><p><strong>Methods: </strong>This was a prospective, observational, multicentre, cohort study in patients with UC or CD starting treatment with vedolizumab or other biologics (NCT02674308, EUPAS6469). The primary safety outcome was serious infections compared between cohorts using a Cox proportional hazards model adjusted by propensity score. Clinical effectiveness was a secondary outcome.</p><p><strong>Results: </strong>The full analysis set comprised 5,008 pts (vedolizumab=2,502; other biologic=2,506) and mean (standard deviation) follow-up duration was 37.4 (14.1) months. Patients in the vedolizumab group had greater age, duration of disease, and concomitant medication use at baseline, indicating more advanced disease. In patients with UC, the incidence rate per 100 person-years of serious infections was: 5.5 (95% CI: 4.7, 6.5) [vedolizumab] and 7.0 (5.8, 8.5) [other biologic], with an adjusted hazard ratio (HR) of 0.89 (0.69, 1.15), p=0.38. In patients with CD, corresponding findings were 7.9 (95% CI: 6.8, 9.1) [vedolizumab] and 6.5 (95% CI: 5.7, 7.3) [other biologic] with adjusted HR of 1.15 (0.95, 1.40), p=0.16. There were no safety issues relating to pregnancy and no cases of progressive multifocal leukoencephalopathy were observed. There were 18 deaths in the vedolizumab group and 13 in the other biologic group. Clinical effectiveness was comparable between cohorts and was similar to the levels seen in other prospective observations of vedolizumab.</p><p><strong>Conclusion: </strong>There was no new safety signal identified in relation to vedolizumab. Results regarding safety and effectiveness were consistent with the known profile of vedolizumab.</p>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":12.0000,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Gastroenterology and Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cgh.2025.10.006","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and aims: This post-authorization safety study compared long-term safety of vedolizumab or other biologics in patients with ulcerative colitis (UC) or Crohn's disease (CD).
Methods: This was a prospective, observational, multicentre, cohort study in patients with UC or CD starting treatment with vedolizumab or other biologics (NCT02674308, EUPAS6469). The primary safety outcome was serious infections compared between cohorts using a Cox proportional hazards model adjusted by propensity score. Clinical effectiveness was a secondary outcome.
Results: The full analysis set comprised 5,008 pts (vedolizumab=2,502; other biologic=2,506) and mean (standard deviation) follow-up duration was 37.4 (14.1) months. Patients in the vedolizumab group had greater age, duration of disease, and concomitant medication use at baseline, indicating more advanced disease. In patients with UC, the incidence rate per 100 person-years of serious infections was: 5.5 (95% CI: 4.7, 6.5) [vedolizumab] and 7.0 (5.8, 8.5) [other biologic], with an adjusted hazard ratio (HR) of 0.89 (0.69, 1.15), p=0.38. In patients with CD, corresponding findings were 7.9 (95% CI: 6.8, 9.1) [vedolizumab] and 6.5 (95% CI: 5.7, 7.3) [other biologic] with adjusted HR of 1.15 (0.95, 1.40), p=0.16. There were no safety issues relating to pregnancy and no cases of progressive multifocal leukoencephalopathy were observed. There were 18 deaths in the vedolizumab group and 13 in the other biologic group. Clinical effectiveness was comparable between cohorts and was similar to the levels seen in other prospective observations of vedolizumab.
Conclusion: There was no new safety signal identified in relation to vedolizumab. Results regarding safety and effectiveness were consistent with the known profile of vedolizumab.
期刊介绍：
Clinical Gastroenterology and Hepatology (CGH) is dedicated to offering readers a comprehensive exploration of themes in clinical gastroenterology and hepatology. Encompassing diagnostic, endoscopic, interventional, and therapeutic advances, the journal covers areas such as cancer, inflammatory diseases, functional gastrointestinal disorders, nutrition, absorption, and secretion.
As a peer-reviewed publication, CGH features original articles and scholarly reviews, ensuring immediate relevance to the practice of gastroenterology and hepatology. Beyond peer-reviewed content, the journal includes invited key reviews and articles on endoscopy/practice-based technology, health-care policy, and practice management. Multimedia elements, including images, video abstracts, and podcasts, enhance the reader's experience. CGH remains actively engaged with its audience through updates and commentary shared via platforms such as Facebook and Twitter.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
